CN110237260A - 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 - Google Patents

包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 Download PDF

Info

Publication number
CN110237260A
CN110237260A CN201910504867.3A CN201910504867A CN110237260A CN 110237260 A CN110237260 A CN 110237260A CN 201910504867 A CN201910504867 A CN 201910504867A CN 110237260 A CN110237260 A CN 110237260A
Authority
CN
China
Prior art keywords
budesonide
pharmaceutical composition
pharmaceutically acceptable
present
tiotropium bromide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910504867.3A
Other languages
English (en)
Chinese (zh)
Inventor
G·马尔霍特拉
S·M·普兰德尔
A·卢拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cipla Ltd
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of CN110237260A publication Critical patent/CN110237260A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201910504867.3A 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物 Pending CN110237260A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
IN2051/MUM/2010 2010-07-16
IN2051MU2010 2010-07-16
IN3157MU2010 2010-11-18
IN3156MU2010 2010-11-18
IN3157/MUM/2010 2010-11-18
IN3156/MUM/2010 2010-11-18
CN2011800395439A CN103096897A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800395439A Division CN103096897A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物

Publications (1)

Publication Number Publication Date
CN110237260A true CN110237260A (zh) 2019-09-17

Family

ID=44629226

Family Applications (3)

Application Number Title Priority Date Filing Date
CN2011800395439A Pending CN103096897A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
CN201910504867.3A Pending CN110237260A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物
CN201510665216.4A Pending CN105412122A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN2011800395439A Pending CN103096897A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201510665216.4A Pending CN105412122A (zh) 2010-07-16 2011-07-18 包含r(+)布地奈德和一种或多种支气管扩张剂的药物组合物

Country Status (13)

Country Link
US (4) US20130274232A1 (enExample)
EP (2) EP3871676A1 (enExample)
JP (3) JP2013531056A (enExample)
KR (2) KR20140020815A (enExample)
CN (3) CN103096897A (enExample)
AU (1) AU2011278096B2 (enExample)
BR (1) BR112013001119A2 (enExample)
CA (1) CA2805700A1 (enExample)
MX (1) MX2013000642A (enExample)
NZ (1) NZ605920A (enExample)
RU (1) RU2568882C2 (enExample)
WO (1) WO2012007729A2 (enExample)
ZA (1) ZA201300718B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013001119A2 (pt) 2010-07-16 2016-05-24 Cipla Ltd composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
AU2013336492A1 (en) * 2012-10-23 2015-04-09 Cipla Limited Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane
MX368036B (es) * 2013-08-05 2019-09-17 Chemo Res S L Particulas inhalables que comprenden tiotropio e indacaterol.
CN104744271B (zh) * 2013-12-26 2016-08-31 成都伊诺达博医药科技有限公司 一种合成维兰特罗的新工艺
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
WO2016018892A1 (en) 2014-07-29 2016-02-04 3M Innovative Properties Company Method of preparing a pharmaceutical composition
CN104606205A (zh) * 2015-01-13 2015-05-13 段希福 一种奥达特罗和布地奈德的药物组合物及其用途
EP3701940B1 (en) * 2015-12-04 2025-11-12 Mexichem Fluor S.A. de C.V. Pharmaceutical composition
CN106466322A (zh) * 2016-08-25 2017-03-01 杭州百诚医药科技股份有限公司 一种以布地奈德和噻托溴铵为活性成分的复方制剂
WO2019142214A1 (en) * 2018-01-19 2019-07-25 Cipla Limited Pharmaceutical composition comprising tiotropium for inhalation
MA52756A (fr) * 2018-06-04 2021-04-14 Lupin Inc Compositions pharmaceutiques stables pour inhalateurs doseurs sous pression
WO2020141472A1 (en) * 2019-01-03 2020-07-09 Glenmark Specialty S.A. Nebulization composition comprising tiotropium and indacaterol
CN110051629A (zh) * 2019-05-17 2019-07-26 南京望知星医药科技有限公司 一种用于治疗呼吸疾病的雾化沙丁胺醇溶液及其制备方法
GB202001537D0 (en) * 2020-02-05 2020-03-18 Consort Medical Plc Pressurised dispensing container
CN111481550A (zh) * 2020-05-14 2020-08-04 王兆霖 含有噻托溴铵和阿福特罗的药物制剂
WO2021262675A1 (en) * 2020-06-23 2021-12-30 Anovent Pharmaceutical (U.S.), Llc Preparation of a pharmaceutical composition of olodaterol, tiotropium bromide and budesonide
WO2022073009A1 (en) 2020-09-29 2022-04-07 iPharma Labs, Inc. Liquid formulations of indacaterol
US20240156734A1 (en) * 2022-11-11 2024-05-16 Michael Farber Simplified Method for Making Shelf Stable Highly Water Soluble Anhydrous Compositions Of Cyclodextrin Complexes of Macrocyclic Lactones

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305380A (zh) * 1998-06-11 2001-07-25 阿斯特拉曾尼卡有限公司 含有福莫特罗和布地奈德的组合物在预防和治疗急性气喘疾病中的应用
JP2004515454A (ja) * 2000-05-12 2004-05-27 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 気管支肺疾患の治療のためのグルココルチコイド薬物を含有する製剤
JP2006509776A (ja) * 2002-11-29 2006-03-23 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 吸入用チオトロピウム含有医薬品組成物
CN1753678A (zh) * 2003-02-27 2006-03-29 奇斯药制品公司 包含高效长效β2－激动剂和其它活性成分的药物组合物
US20080182831A1 (en) * 2005-01-10 2008-07-31 Glaxo Group Limited Androstane 17-Alpha Carbonate Derivatives for Use in the Treatment of Allergic and Inflammatory Conditions
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
SE9900834D0 (sv) * 1999-03-09 1999-03-09 Astra Ab Novel combination
GB0009613D0 (en) 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009584D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Pharmaceutical compositions
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
GB0029562D0 (en) * 2000-12-04 2001-01-17 Novartis Ag Organic compounds
DE10130371A1 (de) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
US20040247530A1 (en) * 2001-08-07 2004-12-09 Arthur Deboeck Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respitory disorders
US20040258730A1 (en) 2001-11-12 2004-12-23 Yasuhiko Tabata Persistent filmy preparation for topical administration containing prostglandin derivative
KR20030065831A (ko) 2002-02-01 2003-08-09 주식회사 태평양 사이클로스포린을 함유한 지속 방출형 약학적 조성물
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
EP1415647A1 (en) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. "Long-acting beta-2 agonists ultrafine formulations"
AU2003222753B2 (en) 2002-03-01 2008-04-17 Chiesi Farmaceutici S.P.A. Formoterol superfine formulation
EP1531866A1 (en) 2002-08-29 2005-05-25 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
WO2004028545A1 (en) 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US6840529B2 (en) * 2002-10-17 2005-01-11 David B. Call Articulated pickup truck camper/trailer
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7250426B2 (en) * 2002-11-29 2007-07-31 Boehringer Ingelheim Pharma Gmbh & Co Kg Tiotropium-containing pharmaceutical combination for inhalation
SE527190C2 (sv) 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid
TWI359675B (en) * 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020298A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
DE602005026225D1 (de) 2004-03-12 2011-03-24 Cipla Ltd Sterilisationsprozess für Steroide
GB0415789D0 (en) 2004-07-15 2004-08-18 Astrazeneca Ab Novel combination
RU2440972C2 (ru) 2004-12-17 2012-01-27 Сипла Лимитед Кристаллический сульфат левосальбутамола, способ его получения и фармацевтическая композиция, содержащая его
MX2007012084A (es) * 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
JP2010519195A (ja) * 2007-02-19 2010-06-03 シプラ・リミテッド 薬学的組成物
EP2011534A1 (en) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Metered dose inhaler actuator
BR112013001119A2 (pt) 2010-07-16 2016-05-24 Cipla Ltd composição farmacêutica, processo para fabricar uma composição farmacêutica, uso de r(+)budesonida e um broncodilatador, e método de profilaxia ou tratamento de uma doença respiratória, inflamatória ou obstrutiva das vias aéreas
WO2012049444A1 (en) 2010-10-12 2012-04-19 Cipla Limited Pharmaceutical composition
MX2014011576A (es) 2012-04-11 2014-11-21 Cipla Ltd Composicion farmaceutica.
US9913853B2 (en) 2015-11-03 2018-03-13 Cipla Limited Stabilized liquid fosaprepitant formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305380A (zh) * 1998-06-11 2001-07-25 阿斯特拉曾尼卡有限公司 含有福莫特罗和布地奈德的组合物在预防和治疗急性气喘疾病中的应用
JP2004515454A (ja) * 2000-05-12 2004-05-27 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 気管支肺疾患の治療のためのグルココルチコイド薬物を含有する製剤
JP2006509776A (ja) * 2002-11-29 2006-03-23 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 吸入用チオトロピウム含有医薬品組成物
CN1753678A (zh) * 2003-02-27 2006-03-29 奇斯药制品公司 包含高效长效β2－激动剂和其它活性成分的药物组合物
US20080182831A1 (en) * 2005-01-10 2008-07-31 Glaxo Group Limited Androstane 17-Alpha Carbonate Derivatives for Use in the Treatment of Allergic and Inflammatory Conditions
CN101249093A (zh) * 2008-03-19 2008-08-27 李虎山 一种治疗慢性阻塞性肺部疾病的组合物

Also Published As

Publication number Publication date
US20130274232A1 (en) 2013-10-17
WO2012007729A3 (en) 2012-05-31
JP2017039736A (ja) 2017-02-23
JP2018199684A (ja) 2018-12-20
ZA201300718B (en) 2013-08-28
JP2013531056A (ja) 2013-08-01
US20130330281A1 (en) 2013-12-12
CA2805700A1 (en) 2012-01-19
KR20180091120A (ko) 2018-08-14
EP2593108A2 (en) 2013-05-22
EP3871676A1 (en) 2021-09-01
US20210308150A1 (en) 2021-10-07
BR112013001119A2 (pt) 2016-05-24
MX2013000642A (es) 2013-04-03
RU2013106866A (ru) 2014-08-27
US20170333452A1 (en) 2017-11-23
KR20140020815A (ko) 2014-02-19
NZ605920A (en) 2015-01-30
US11077124B2 (en) 2021-08-03
RU2568882C2 (ru) 2015-11-20
CN103096897A (zh) 2013-05-08
CN105412122A (zh) 2016-03-23
AU2011278096A1 (en) 2013-02-14
AU2011278096B2 (en) 2014-08-28
WO2012007729A2 (en) 2012-01-19
US12472190B2 (en) 2025-11-18

Similar Documents

Publication Publication Date Title
US12472190B2 (en) Pharmaceutical compositions
JP2019038818A (ja) 医薬組成物
CN103269694A (zh) 药物组合物
WO2014016548A2 (en) Pharmaceutical composition
JP2018058881A (ja) 医薬組成物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190917

RJ01 Rejection of invention patent application after publication